These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 8164356)

  • 1. [Action mechanism of synthetic androgens].
    Matsumoto K; Namiki M
    Nihon Rinsho; 1994 Mar; 52(3):600-5. PubMed ID: 8164356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot.
    Handelsman DJ; Conway AJ; Howe CJ; Turner L; Mackey MA
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4113-21. PubMed ID: 8923869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical use of androgenic steroids at a major medical center: who prescribes androgens and how well do they do it?
    Cavanah SF; Jacobson JM; McIntyre T
    J Clin Pharmacol; 1993 Mar; 33(3):253-8. PubMed ID: 8463439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An effective hormonal male contraceptive using testosterone undecanoate with oral or injectable norethisterone preparations.
    Kamischke A; Heuermann T; Krüger K; von Eckardstein S; Schellschmidt I; Rübig A; Nieschlag E
    J Clin Endocrinol Metab; 2002 Feb; 87(2):530-9. PubMed ID: 11836281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of spermatogenesis by testosterone enanthate in Thai men.
    Aribarg A; Sukcharoen N; Chanprasit Y; Ngeamvijawat J; Kriangsinyos R
    J Med Assoc Thai; 1996 Oct; 79(10):624-9. PubMed ID: 8996996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Anabolic agents (synthetic androgens) in oncology, with special reference to breast carcinoma].
    PIACENTINI G
    Clin Ter; 1962 Aug; 23():197-214. PubMed ID: 13943190
    [No Abstract]   [Full Text] [Related]  

  • 7. Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception.
    Behre HM; Nashan D; Hubert W; Nieschlag E
    J Clin Endocrinol Metab; 1992 Jan; 74(1):84-90. PubMed ID: 1727833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic indications for delayed puberty and hypogonadism in adolescent boys.
    Zachmann M
    Horm Res; 1991; 36(3-4):141-6. PubMed ID: 1818010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The treatment of hypogonadism and maintenance of fertility in men].
    Rabijewski M
    Pol Merkur Lekarski; 2016 Mar; 40(237):198-201. PubMed ID: 27088205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress towards hormonal male contraception.
    Kamischke A; Nieschlag E
    Trends Pharmacol Sci; 2004 Jan; 25(1):49-57. PubMed ID: 14723979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dissociation of growth-stimulating and skeleton-maturing actions of the synthetic androgen, fluoxymesterone.
    REILLY WA; GORDAN GS
    J Pediatr; 1961 Aug; 59():188-93. PubMed ID: 13740537
    [No Abstract]   [Full Text] [Related]  

  • 12. Hormonal therapy of male hypogonadism.
    Matsumoto AM
    Endocrinol Metab Clin North Am; 1994 Dec; 23(4):857-75. PubMed ID: 7705324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders.
    Behre HM; Baus S; Kliesch S; Keck C; Simoni M; Nieschlag E
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2394-403. PubMed ID: 7543113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological activity of hormonally active and non-active androgen derivatives.
    Vojtísková M; Dráber P; Veres K; Pokorná Z
    Int J Immunopharmacol; 1982; 4(5):469-74. PubMed ID: 7129718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocrine evaluation and therapy of erectile dysfunction.
    McClure RD
    Urol Clin North Am; 1988 Feb; 15(1):53-64. PubMed ID: 3278476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. III. Higher 5 alpha-reductase activity in oligozoospermic men administered supraphysiological doses of testosterone.
    Anderson RA; Wallace AM; Wu FC
    J Clin Endocrinol Metab; 1996 Mar; 81(3):902-8. PubMed ID: 8772548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective androgen receptor modulators for frailty and osteoporosis.
    Kilbourne EJ; Moore WJ; Freedman LP; Nagpal S
    Curr Opin Investig Drugs; 2007 Oct; 8(10):821-9. PubMed ID: 17907058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach.
    Bebb RA; Anawalt BD; Christensen RB; Paulsen CA; Bremner WJ; Matsumoto AM
    J Clin Endocrinol Metab; 1996 Feb; 81(2):757-62. PubMed ID: 8636300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of various modes of androgen substitution therapy on erythropoiesis.
    Jockenhövel F; Vogel E; Reinhardt W; Reinwein D
    Eur J Med Res; 1997 Jul; 2(7):293-8. PubMed ID: 9233903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgens and male sexual function: a review of human studies.
    Schiavi RC; White D
    J Sex Marital Ther; 1976; 2(3):214-28. PubMed ID: 1034710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.